China SXT Pharmaceuticals Inc (SXTC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $310,720
Last updated: Nov 17, 2026 at 11:05 AM ET
China SXT Pharmaceuticals Inc (SXTC) Financials: Revenue, Profit and Cash Flow
China SXT Pharmaceuticals reported revenue of $1.07M for the fiscal year ended Mar 31, 2026, down 38.4% from the year before. That year, net income was -$6.21M with a net margin of -578.5%, operating cash flow was -$4.02M and free cash flow was -$4.02M. The quarter ended Jun 30, 2026 had revenue of $1.20M and net income of $163.72K.
Revenue and Margins
Over the 9 years to Mar 2026, revenue fell from $4.88M, a compound annual decline of 15.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $1.07M | -38.4% | 17.1% | -664.1% | -578.5% |
| Mar 2025 | $1.74M | -9.7% | 21.1% | -154.0% | -189.8% |
| Mar 2024 | $1.93M | -2.2% | 28.7% | -130.4% | -160.7% |
| Mar 2023 | $1.97M | -24.2% | 21.6% | -284.4% | -301.0% |
| Mar 2022 | $2.60M | -45.5% | 48.1% | -199.4% | -220.4% |
| Mar 2021 | $4.78M | -7.5% | 59.4% | -46.0% | -57.5% |
| Mar 2020 | $5.16M | -26.4% | 52.4% | -26.0% | -199.3% |
| Mar 2019 | $7.01M | -0.1% | 65.8% | 25.2% | 22.0% |
| Mar 2018 | $7.02M | +43.8% | 48.5% | 23.3% | 16.9% |
| Mar 2017 | $4.88M | N/A | 47.4% | 32.8% | 24.3% |
Income Statement
In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07M | $1.74M | $1.93M | $1.97M | $2.60M | $4.78M | $5.16M | $7.01M | $7.02M | $4.88M |
| Cost of revenue | $889.35K | $1.37M | $1.37M | $1.55M | $1.35M | $1.94M | $2.46M | $2.40M | $3.62M | $2.57M |
| Gross profit | $183.28K | $367.43K | $553.97K | $426.27K | $1.25M | $2.84M | $2.70M | $4.61M | $3.40M | $2.31M |
| Research and development | $178.76K | $191.39K | $184.19K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$7.12M | -$2.68M | -$2.52M | -$5.61M | -$5.19M | -$2.20M | -$1.34M | $1.77M | $1.63M | $1.60M |
| Net income | -$6.21M | -$3.30M | -$3.10M | -$5.93M | -$5.74M | -$2.75M | -$10.29M | $1.54M | $1.19M | $1.19M |
| EBITDA | -$6.98M | -$2.57M | -$2.35M | -$5.21M | -$5.05M | -$1.85M | -$1.01M | $1.98M | $1.76M | $1.70M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.20M | $255.74K | $626.57K | -$1.01M | $455.71K | $414.75K | $751.07K | $898.16K | $469.79K | $381.70K | $1.21M | -$11.50M |
| Gross profit | $833.97K | $73.49K | $101.72K | -$825.90K | $116.34K | $67.38K | $389.43K | $144.17K | $144.17K | $168.29K | $89.68K | -$15.53M |
| Operating income | -$784.01K | -$392.00K | -$6.34M | -$3.17M | -$1.02M | -$319.13K | $3.42M | -$4.67M | -$4.67M | -$2.23M | -$1.15M | $1.28M |
| Net income | $163.72K | $81.86K | -$6.37M | -$81.86K | -$1.25M | -$401.28K | $3.30M | -$4.85M | -$4.85M | -$2.22M | -$1.49M | $2.32M |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded total debt of $1.07M by $27.11M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $34.75M | $21.66M | $23.13M | $29.55M | $33.55M | $34.55M | $21.70M | $17.47M | $7.66M | $5.43M |
| Current assets | $34.51M | $21.30M | $14.23M | $19.52M | $22.45M | $23.23M | $19.64M | $15.59M | $6.10M | $4.91M |
| Cash and equivalents | $28.18M | $18.10M | $12.07M | $17.37M | $15.52M | $13.33M | $7.29M | $9.13M | $560.25K | $65.57K |
| Total liabilities | $5.05M | $6.22M | $9.20M | $14.86M | $17.12M | $18.59M | $12.30M | $6.36M | $4.37M | $3.58M |
| Short-term debt | $423.15K | $772.19K | $2.35M | $3.39M | $10.74M | $37.12K | $6.69M | $2.74M | $385.12K | $302.17K |
| Long-term debt | $644.39K | $96.26K | $117.13K | $117.86K | N/A | $6.29K | $36.51K | N/A | N/A | N/A |
| Shareholder equity | $29.71M | $15.44M | $13.93M | $14.69M | $16.42M | $15.96M | $9.40M | $11.11M | $3.29M | $1.85M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $34.75M | $34.75M | $34.75M | $26.35M | $26.35M | $21.66M | $21.66M | $29.99M | $31.00M | $23.13M | $23.13M | $14.59M |
| Total liabilities | $5.05M | $5.05M | $5.05M | $6.12M | $6.12M | $6.22M | $6.22M | $19.81M | $15.96M | $9.20M | $9.20M | $9.52M |
| Cash and equivalents | $28.18M | $28.18M | $28.18M | $21.17M | $21.17M | $18.10M | $18.10M | N/A | $18.51M | $12.07M | $12.07M | $11.47M |
| Shareholder equity | $29.71M | $29.71M | $29.71M | $20.23M | $20.23M | $15.44M | $15.44M | $10.18M | $15.03M | $13.93M | $13.93M | $5.08M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.02M | -$2.35M | -$1.93M | -$80.76K | -$2.37M | -$1.32M | $934.25K | $239.19K | $1.92M | $293.04K |
| Capital expenditures | $4 | $2.02K | $7.06K | $70.68K | $62.49K | $93.04K | $406.66K | $610.09K | $1.05M | $186.31K |
| Free cash flow | -$4.02M | -$2.35M | -$1.94M | -$151.44K | -$2.44M | -$1.41M | $527.59K | -$370.89K | $869.44K | $106.73K |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.38M | N/A | N/A |
| Investing cash flow | -$1.25M | $63.52K | $26.42K | -$12.30K | -$46.91K | -$5.81M | -$5.50M | -$610.09K | -$1.14M | -$186.31K |
| Financing cash flow | $14.43M | $8.40M | -$2.62M | $2.94M | $1.63M | $12.41M | $3.02M | $9.04M | -$314.22K | -$50.56K |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.26M | -$1.13M | -$1.75M | -$876.28K | -$719.89K | -$664.79K | -$674.24K | -$141.63K | -$289.78K | N/A | $234.18K |
| Capital expenditures | $0 | $0 | $4 | $988.15K | $1.01K | $3.53K | $3.53K | $0 | $50.57K | $0 | $25.28K |
| Free cash flow | -$2.26M | -$1.13M | -$1.75M | -$1.86M | -$720.90K | -$668.33K | -$677.77K | -$141.63K | -$340.35K | N/A | $208.90K |
Frequently Asked Questions About SXTC
What is China SXT Pharmaceuticals' annual revenue?
China SXT Pharmaceuticals reported revenue of $1.07M for the fiscal year ended Mar 31, 2026.
How fast is China SXT Pharmaceuticals' revenue growing?
Revenue was down 38.4% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -18.4%.
Is China SXT Pharmaceuticals profitable?
No. China SXT Pharmaceuticals reported net income of -$6.21M for the fiscal year ended Mar 31, 2026, with a net margin of -578.5%.
How much free cash flow does SXTC generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$4.02M minus capital expenditures of $4 produced free cash flow of -$4.02M.
How much debt does China SXT Pharmaceuticals have?
The balance sheet dated Mar 31, 2026 reported long-term debt of $644.39K, short-term debt of $423.15K and cash and equivalents of $28.18M.
SXTC pages: Overview, Financials